UPDATE
: 2021.1.20 06:34
WITH ī(MCIL) ̵
ó
α
ȸ
Medi Academy Archive
Clinical Selection
Medi Treat & Law
M Channel Archive
Medi
Pharmacy
Observation
Policy
Global
Opinion
Issue
ī(MCIL)
û
ü纸
ܿ
ν ÷翣 ġ ÷, Ȯ롦1ȸ 汸 ÷翣 ȯڿ Ȳ ' ȿ' Ȯ
ν ÷翣 ġ ÷, Ȯ롦1ȸ 汸 ÷翣 ȯڿ Ȳ ' ȿ' Ȯ
̿ '۷ι ̵ (VIRTUAL PHARMA MEDIA DAY)' ֡'ȭϴ コɾ, ȭϴ ̿ ' ̿ ٽɵ 'ȯ ֵ コ ַ о ' Ұ
̿ '۷ι ̵ (VIRTUAL PHARMA MEDIA DAY)' ֡'ȭϴ コɾ, ȭϴ ̿ ' ̿ ٽɵ 'ȯ ֵ コ ַ о ' Ұ
ľó ' ġ ž 㰡'31° ž '' 㰡
ľó ' ġ ž 㰡'31° ž '' 㰡
icon
ѵ, 索 ȯ '߰ 縻' 1õ 7 ӷ Ρ' ǥ ' ʿ ȯ쿡 '索 縻'
icon
ѱǻѱƽƮī, '索 α üᡤ1ȸ ' ǥ'索 ġ ' 'ǰ ȯ ǰ '
icon
ѱֺ, ϼ ' ģ ' ' 桤ź ٹ' 2015 ̾ ' ģ '
Clinical Selection
ν ÷翣 ġ ÷, Ȯ롦1ȸ 汸 ÷翣 ȯڿ Ȳ ' ȿ' Ȯ
ν ÷翣 ġ ÷, Ȯ롦1ȸ 汸 ÷翣 ȯڿ Ȳ ' ȿ' Ȯ
'̼Ƹ 3 ӻ(Rainbow)' 'Anti-VEGF ȿ' ȮΡƼ 缾Ƽ, '̼Ƹ 索 ' Ȯ
'̼Ƹ 3 ӻ(Rainbow)' 'Anti-VEGF ȿ' ȮΡƼ 缾Ƽ, '̼Ƹ 索 ' Ȯ
ѱἾ ڶ, ' Ȱ ˾缺 忰 ġ ' Ρ"ߵ ˾缺 忰 ȯڵ鿡 ο ġ ɼ "
ѱἾ ڶ, ' Ȱ ˾缺 忰 ġ ' Ρ"ߵ ˾缺 忰 ȯڵ鿡 ο ġ ɼ "
ֺ, 'KEEPsAKE-1KEEPsAKE-2' ౺ Űָ(150mg) ǹϰ ȯڵ 1 24 ACR20 ǥ
ֺ, 'KEEPsAKE-1KEEPsAKE-2' ౺ Űָ(150mg) ǹϰ ȯڵ 1 24 ACR20 ǥ
Medi Academy Archive
ġȸ, ⺻ ֽ ġ 'ġ ӻ ' 3 ࡦġ ֽ ġ ȯ 깰 10⸸
ġȸ, ⺻ ֽ ġ 'ġ ӻ ' 3 ࡦġ ֽ ġ ȯ 깰 10⸸
ȸ, ġ ϱ ' ķ' ࡦ ȯ 384 12%
ȸ, ġ ϱ ' ķ' ࡦ ȯ 384 12%
ѽȸ, Ϻ ȯ ǻ ӻ
ѽȸ, Ϻ ȯ ǻ ӻ
'ƽþƿȯмȸ' Ȳ 'Gateway to Excellence in IBD Research and Practice ''36 1500 Ƿ'
'ƽþƿȯмȸ' Ȳ 'Gateway to Excellence in IBD Research and Practice ''36 1500 Ƿ'
Medi Treat & Law
GC ڷγ19 ġ 'GC5131' ġ 2 Ρ'GC5131' ġ ' 10 2 30' ġ
GC ڷγ19 ġ 'GC5131' ġ 2 Ρ'GC5131' ġ ' 10 2 30' ġ
ѹ̾ǰ 'Ҹ˼ĸ20и'̿ 'ī100/1000' 'θֻ' żѱἾ 'ڶʵ'ȭ 'ڸĸ250и' ѱݾ
ѹ̾ǰ 'Ҹ˼ĸ20и'̿ 'ī100/1000' 'θֻ' żѱἾ 'ڶʵ'ȭ 'ڸĸ250и' ѱݾ
ֱ 1ϰ GC ڷγ19 ġ 'GC5131A' ġ 8 Ÿ'GC5131A' ڷγ19 ġ 弭 鿪 ü Ǿǰ
ֱ 1ϰ GC ڷγ19 ġ 'GC5131A' ġ 8 Ÿ'GC5131A' ڷγ19 ġ 弭 鿪 ü Ǿǰ
Glecaprevir+Pibrentasvir 汸('') 3 C ȯ 溯 ִ ' Ⱓ 12ּ 8'
Glecaprevir+Pibrentasvir 汸('') 3 C ȯ 溯 ִ ' Ⱓ 12ּ 8'
M Channel Archive
ȭǰ ȣ ̻, 'ö Ŷ ç'
ȭǰ ȣ ̻, 'ö Ŷ ç'
ѱMSD, 'ַ̱ 20Ⱓ ƺ ð' 'ȯڿ Բ ȣϸ ַ̱ 20 ƺ ÿ ο '
ѱMSD, 'ַ̱ 20Ⱓ ƺ ð' 'ȯڿ Բ ȣϸ ַ̱ 20 ƺ ÿ ο '
ѱƽƮī 'ȸ Ǻλ 2 ' 'ȸ Ȱȸ Ȱȭ '
ѱƽƮī 'ȸ Ǻλ 2 ' 'ȸ Ȱȸ Ȱȭ '
ѱǰ, ' ȯ ϴ ķ' ࡦ'â ¾ ȯ Ȱ' ǽ
ѱǰ, ' ȯ ϴ ķ' ࡦ'â ¾ ȯ Ȱ' ǽ
Pharmacy Archive
ѱǻѱƽƮī, '索 α üᡤ1ȸ ' ǥ'索 ġ ' 'ǰ ȯ ǰ '
ѱǻѱƽƮī, '索 α üᡤ1ȸ ' ǥ'索 ġ ' 'ǰ ȯ ǰ '
̿ '۷ι ̵ (VIRTUAL PHARMA MEDIA DAY)' ֡'ȭϴ コɾ, ȭϴ ̿ ' ̿ ٽɵ 'ȯ ֵ コ ַ о ' Ұ
̿ '۷ι ̵ (VIRTUAL PHARMA MEDIA DAY)' ֡'ȭϴ コɾ, ȭϴ ̿ ' ̿ ٽɵ 'ȯ ֵ コ ַ о ' Ұ
ѱֺ, ϼ ' ģ ' ' 桤ź ٹ' 2015 ̾ ' ģ '
ѱֺ, ϼ ' ģ ' ' 桤ź ٹ' 2015 ̾ ' ģ '
ѱȭ 鿪 , ' ķ' 2 ҿ ŵ鿡 õ" ķ, ѱȭ 鿪 ǥ ȸȰ"
ѱȭ 鿪 , ' ķ' 2 ҿ ŵ鿡 õ" ķ, ѱȭ 鿪 ǥ ȸȰ"
Observation
ѵ, 索 ȯ '߰ 縻' 1õ 7 ӷ Ρ' ǥ ' ʿ ȯ쿡 '索 縻'
ȭǰ, Ѹ ġ 'ڸŰ ߽'
ѹ̾ǰ, 'ڷγ19 żŰƮ' 2 ߸š'30 ˻ Ȯ ' ǽ ʱ ܿ
, 'ڷγ19 غ' Ǿǰ ΡǾǰι̿ƽ Ŀ
ȸ コɾ, 'ڸ â ǥâ''ڸ â ̹ '
Medi View Archive
' ' · ߡ뺴 ϴ 'ùٸ 桤ġ'
' ' ·
[ų]ۿ 2021 ų硦'Beyond the Best, ְ ̻' ưô
[ų]ۿ 2021
, '뵿 450'
, '뵿 450'
ARCHIVE
PREV
NEXT
̿ȸ '2023 2 ӱ ' ȸ ̿ ̳뺣̼, ۷ι ּ "
ѵ, 索 ȯ '߰ 縻' 1õ 7 ӷ Ρ' ǥ ' ʿ ȯ쿡 '索 縻'
ν ÷翣 ġ ÷, Ȯ롦1ȸ 汸 ÷翣 ȯڿ Ȳ ' ȿ' Ȯ
ѱǻѱƽƮī, '索 α üᡤ1ȸ ' ǥ'索 ġ ' 'ǰ ȯ ǰ '
̿ '۷ι ̵ (VIRTUAL PHARMA MEDIA DAY)' ֡'ȭϴ コɾ, ȭϴ ̿ ' ̿ ٽɵ 'ȯ ֵ コ ַ о ' Ұ
ľó ' ġ ž 㰡'31° ž '' 㰡
ѱֺ, ϼ ' ģ ' ' 桤ź ٹ' 2015 ̾ ' ģ '
ȭǰ, Ѹ ġ 'ڸŰ ߽'
ѹ̾ǰ, 'ڷγ19 żŰƮ' 2 ߸š'30 ˻ Ȯ ' ǽ ʱ ܿ
, 'ڷγ19 غ' Ǿǰ ΡǾǰι̿ƽ Ŀ
Issue Archive
ľó ' ġ ž 㰡'31° ž '' 㰡
ľó ' ġ ž 㰡'31° ž '' 㰡
Ѿ ̹ ǰ ǽ 2 ӻ(ġ Ž ӻ) 3 ӻ(ġ Ȯ ӻ) ϴ ...
'Ǿǰ ܺ塤' 'ȿɡȿ'Ư ' ' ࡦ÷ι ' ȿ '
'Ǿǰ ܺ塤' 'ȿɡȿ'Ư ' ' ࡦ÷ι ' ȿ '
ǰǾǰó(ó 谭) 17 ౹ ս ִ ϹǾǰ ùٸ ...
ľó 'ڷγ19 ġ 㰡ɻ Ȯ' 'ܺ ڹ ȹ' ڹܡ߾Ӿȸȸ
ľó 'ڷγ19 ġ 㰡ɻ Ȯ' 'ܺ ڹ ȹ' ڹܡ߾Ӿȸȸ
ǰǾǰó ڷγ19 Ȳ , 'ڷγ19 ġ ȿ ...
Opinion Archive
ܿö, 'κ ϰ ǰ Ű TIP'⡤ΰ ʿ
ܿö, 'κ ϰ ǰ Ű TIP'⡤ΰ ʿ
ܿö DZ, Źߡ尩 ָؾ ϴ
ܿö DZ, Źߡ尩 ָؾ ϴ
' ' ʿ ñ⡦ٷ°ҡٰ ϰ ִ , 'ٰ '
' ' ʿ ñ⡦ٷ°ҡٰ ϰ ִ , 'ٰ '
ڳ ִ ġ 'Ҿ'' ˻ ȿ ؾ' ǥ ġ
ڳ ִ ġ 'Ҿ'' ˻ ȿ ؾ' ǥ ġ
People Archive
, '繫 CFO' ԡ' ѱȭ 繫 ' ޡ 繫 õ Ȱ Ѱ
峻б 30 ' ̾߱' Ⱓ
ѱ ƽ-ֺ ۴ ӡ'ѱű 塤 3' η コɾ
GCコɾ, ȿ ǥ̻
̿ȸ '2023 2 ӱ ' ȸ ̿ ̳뺣̼, ۷ι ּ "
̿ȸ '2023 2 ӱ ' ȸ ̿ ̳뺣̼, ۷ι ּ "
ѱ̿ȸ ȸ 2023 2 ̿ Ű ۷ι ...
ѵ, 索 ȯ '߰ 縻' 1õ 7 ӷ Ρ' ǥ ' ʿ ȯ쿡 '索 縻'
ν ÷翣 ġ ÷, Ȯ롦1ȸ 汸 ÷翣 ȯڿ Ȳ ' ȿ' Ȯ
ѱǻѱƽƮī, '索 α üᡤ1ȸ ' ǥ'索 ġ ' 'ǰ ȯ ǰ '
̿ '۷ι ̵ (VIRTUAL PHARMA MEDIA DAY)' ֡'ȭϴ コɾ, ȭϴ ̿ ' ̿ ٽɵ 'ȯ ֵ コ ַ о ' Ұ
ľó ' ġ ž 㰡'31° ž '' 㰡
ѱֺ, ϼ ' ģ ' ' 桤ź ٹ' 2015 ̾ ' ģ '
ȭǰ, Ѹ ġ 'ڸŰ ߽'
ȭǰ, Ѹ ġ 'ڸŰ ߽'
ȭǰ Ѹ ġ 'ڸŰ ߽'<> ߴٰ 18 .ڸŰ ̴߽ ڰ() ˷...
ѹ̾ǰ, 'ڷγ19 żŰƮ' 2 ߸š'30 ˻ Ȯ ' ǽ ʱ ܿ
, 'ڷγ19 غ' Ǿǰ ΡǾǰι̿ƽ Ŀ
ȸ コɾ, 'ڸ â ǥâ''ڸ â ̹ '
" ̷ "-ư
'Ǿǰ ܺ塤' 'ȿɡȿ'Ư ' ' ࡦ÷ι ' ȿ '
ľó 'ڷγ19 ġ 㰡ɻ Ȯ' 'ܺ ڹ ȹ' ڹܡ߾Ӿȸȸ
˻
Clinical Selection
ν ÷翣 ġ ÷, Ȯ롦1ȸ 汸 ÷翣 ȯڿ Ȳ ' ȿ' Ȯ
'̼Ƹ 3 ӻ(Rainbow)' 'Anti-VEGF ȿ' ȮΡƼ 缾Ƽ, '̼Ƹ 索 ' Ȯ
ѱἾ ڶ, ' Ȱ ˾缺 忰 ġ ' Ρ"ߵ ˾缺 忰 ȯڵ鿡 ο ġ ɼ "
ֺ, 'KEEPsAKE-1KEEPsAKE-2' ౺ Űָ(150mg) ǹϰ ȯڵ 1 24 ACR20 ǥ
ġ 'ű' 㰡ű, ݹ(cataplexy) ȯڵ ġ ɼ
ѱ ȿ ν '' 索 ȯ 㰡 Ρ㰡 '1 2 索 ӻ PRONTO ӻ ' ̷
Ƽ, Ʈ Կĸ 㰡 ' ߵ õȯڿ ο ġ ɼ' 3 õ ġ ' Կĸ'ICS/LABA 'Ʈ Կĸ' 㰡
M Channel Archive
ȭǰ ȣ ̻, 'ö Ŷ ç'
ѱMSD, 'ַ̱ 20Ⱓ ƺ ð' 'ȯڿ Բ ȣϸ ַ̱ 20 ƺ ÿ ο '
ѱƽƮī 'ȸ Ǻλ 2 ' 'ȸ Ȱȸ Ȱȭ '
ѱǰ, ' ȯ ϴ ķ' ࡦ'â ¾ ȯ Ȱ' ǽ
ѱ, (CML) ȯ ϴ ' ' 系 ࡦ ǥ " ȯ ǰϰ 'ູ ' ư ֵ ϱ ּ "
1
2
3
4
5
Medi Academy Archive
ġȸ, ⺻ ֽ ġ 'ġ ӻ ' 3 ࡦġ ֽ ġ ȯ 깰 10⸸
ȸ, ġ ϱ ' ķ' ࡦ ȯ 384 12%
ѽȸ, Ϻ ȯ ǻ ӻ
'ƽþƿȯмȸ' Ȳ 'Gateway to Excellence in IBD Research and Practice ''36 1500 Ƿ'
Ѻȸ а 62%, ȯ '() ߺ ɼ' 1
Ѹȸ, 'Ż ȯ νġ Ȳ ' ǥ'10 8 Ǫ Ż ȭ ǰ '
ġȸ̼, ġ ȯ 'ϻ ̼' ֡ 硤̼ ϻȰɷ
Medi Treat & Law
GC ڷγ19 ġ 'GC5131' ġ 2 Ρ'GC5131' ġ ' 10 2 30' ġ
ѹ̾ǰ 'Ҹ˼ĸ20и'̿ 'ī100/1000' 'θֻ' żѱἾ 'ڶʵ'ȭ 'ڸĸ250и' ѱݾ
ֱ 1ϰ GC ڷγ19 ġ 'GC5131A' ġ 8 Ÿ'GC5131A' ڷγ19 ġ 弭 鿪 ü Ǿǰ
Glecaprevir+Pibrentasvir 汸('') 3 C ȯ 溯 ִ ' Ⱓ 12ּ 8'
Imipenem+Cilastatin Doripenem ' ӻħӻ ȸ ǰ ݿ' 㰡 ʰ / ȯڿ Ȯ
1
2
3
4
5
Issue
ľó ' ġ ž 㰡'31° ž '' 㰡
'Ǿǰ ܺ塤' 'ȿɡȿ'Ư ' ' ࡦ÷ι ' ȿ '
ľó 'ڷγ19 ġ 㰡ɻ Ȯ' 'ܺ ڹ ȹ' ڹܡ߾Ӿȸȸ
'Ǿǰ ۿ ر ǡ' ȭ'Ǿǰۿ ȸ ôǡȸ ' ȭ
'ڷγ19 Ư¡ۿ ' ƽƮī šἾ(ص) ̷ š'ȭ š RNA
Archive
1
'̼Ƹ 3 ӻ(Rainbow)' 'Anti-VEGF ȿ' ȮΡƼ 缾Ƽ, '̼Ƹ 索 ' Ȯ
2
" ȯڵ ġ ִ ȯ ϱ ͡뺸 ũ, ȯ ν ķ ' ̾Ʈ?'
3
ѱȭ 鿪 , ' ķ' 2 ҿ ŵ鿡 õ" ķ, ѱȭ 鿪 ǥ ȸȰ"
4
, '繫 CFO' ԡ' ѱȭ 繫 ' ޡ 繫 õ Ȱ Ѱ
5
ľó 'ڷγ19 ġ 㰡ɻ Ȯ' 'ܺ ڹ ȹ' ڹܡ߾Ӿȸȸ
6
峻б 30 ' ̾߱' Ⱓ
7
Ͽ콺Įɾڸ, 'ο ī' á"پ Ʈ ȯ ¡ġ ġῡ "
Policy
' ȭ'' ǸŰ Ģ' Թ
'3 ʰ ó' ȳǷ Ŀ '˸'
ľó, 'Ἶ(ص) ڷγ19 ' ȭڡƽƮī ̾ Ἶ(ص) ڷγ19 㰡û û
ľó 'Ǿǰ 㰡ɻ ' Ȯ롦Ǿǰ 㰡ɻ Ȯ
ľó, 'ȭ ڷγ19 ' ƽƮī ߰ û
Treat Leader Archive
̿ȸ '2023 2 ӱ ' ȸ ̿ ̳뺣̼, ۷ι ּ "
' žళ ¡' Ͼǰ 赿(ȣ) 'ž ؿ ' '۷ι ȭ'' 3,000 Ŭ' Ͼǰ ' ݱ 1,537 100 '
ȸ 輺 ǿ ' Ϻΰ' ǥǡ'ǡ 濪 չû' ó
ǿ, '赿 ȣ ȭ' 赿 ǥǡ ̽ǽ ǰ' ̽ǽ' ǥ
'ѱǾǰҽþ(KIMCo)' 'ȸ GCڡٴ硤ȭǰѹ̾ǰѵȭࡤαǰ 55 ' 1 ̻ȸ ȭ ǥ
' Ƿ ӽ' Ƿ 'Ƿ ȹ' .̷ 'ֿ ȹ'
뺴, Ÿ 300 ' ϰ ΰǸ ''Ǹ- ǥ ' ȯڸ ü
Global
" ̷ "-ư
ڷγ 1000 Ѿ
40 ' ̷ '
ɴ, ' Ϻ ϹǾǰ ٽڻ Ʈ¿ Ű' Ϸᡦɴ, ƽþơ 弭 Ǿǰ ȯ ټ ȭ
, 2 Ǯ ȭ
Observation
ѵ, 索 ȯ '߰ 縻' 1õ 7 ӷ Ρ' ǥ ' ʿ ȯ쿡 '索 縻'
ȭǰ, Ѹ ġ 'ڸŰ ߽'
ѹ̾ǰ, 'ڷγ19 żŰƮ' 2 ߸š'30 ˻ Ȯ ' ǽ ʱ ܿ
, 'ڷγ19 غ' Ǿǰ ΡǾǰι̿ƽ Ŀ
ȸ コɾ, 'ڸ â ǥâ''ڸ â ̹ '
Back to Top